Abandoned trial: could a platelet booster help aplastic anemia?

NCT ID NCT05018936

Terminated Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test the drug hetrombopag in people with non-severe aplastic anemia, a condition where the bone marrow doesn't make enough blood cells. The goal was to see if the drug could safely raise platelet counts. However, the trial was withdrawn before enrolling any participants, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hetrombopag (a drug that helps increase platelet counts)
What this could lead to: If it had worked, this could have pointed toward a new treatment option for people with non-severe aplastic anemia who have low platelet counts.
What could go wrong: This trial was withdrawn before it even started, so no results are available. The approach was still experimental and had not been tested in this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANEMIA DRUG EFFECT

Contacts and locations

Locations

Peking Union Medical College Hospital

Beijing, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.